All patients
PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), durvalumab plus tremelimumab vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18]
0.92 [0.79 ; 1.07 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 1,069 moderate not evaluable progression or deaths (PFS)detailed results MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53]
1.05 [0.72 ; 1.53 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 325 NA not evaluable objective responses (ORR)detailed results MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37]
0.87 [0.55 ; 1.37 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 325 NA not evaluable AE (any grade)detailed results MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24]
0.48 [0.28 ; 0.84 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 1,039 moderate not evaluable AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35]
0.97 [0.76 ; 1.24 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 1,039 moderate not evaluable AE leading to death (grade 5)detailed results MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59]
2.48 [1.45 ; 4.24 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 1,039 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93]
1.49 [1.08 ; 2.05 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 1,039 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
2.14 [1.32 ; 3.47 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable SAE (any grade)detailed results MYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04]
1.93 [1.22 ; 3.04 ] MYSTIC (DT ; PDL1>25%), 2020 1 0% 316 NA not evaluable STRAE (any grade)detailed results MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87]
1.35 [0.96 ; 1.89 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 7% 1,039 moderate not evaluable STRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.43 [0.92 ; 2.21 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable TRAE (any grade)detailed results MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30]
0.24 [0.13 ; 0.43 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 68% 1,039 moderate not evaluable TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60]
0.47 [0.31 ; 0.70 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 46% 1,039 moderate not evaluable TRAE leading to death (grade 5)detailed results MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13]
1.66 [0.48 ; 5.76 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 1,039 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03]
1.31 [0.90 ; 1.92 ] MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 2 0% 1,039 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
2.95 [1.51 ; 5.78 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
5.73 [0.29 ; 114.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.01 [0.00 ; 0.19 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Asthenia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.06 [0.00 ; 1.01 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Colitis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
13.52 [0.76 ; 239.13 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Constipation TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.47 [0.02 ; 14.16 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.95 [0.24 ; 3.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diabetes TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
4.35 [0.93 ; 20.28 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Fatigue TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
1.09 [0.39 ; 3.03 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
13.52 [0.76 ; 239.13 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
5.73 [0.29 ; 114.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Nausea TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.16 [0.02 ; 1.30 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Nephritis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.01 [0.00 ; 0.20 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
7.74 [0.96 ; 62.17 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pruritus TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Rash TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
0.95 [0.06 ; 15.23 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Vomiting TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Alopecia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.12 [0.05 ; 0.28 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Asthenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.86 [0.36 ; 2.05 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Back pain AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.63 [0.10 ; 3.80 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Constipation AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.90 [0.17 ; 21.07 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Cough AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.43 [0.40 ; 5.11 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
2.12 [0.73 ; 6.17 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
1.11 [0.37 ; 3.33 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Fatigue AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31]
1.31 [0.52 ; 3.31 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Nausea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.63 [0.18; 2.25]
0.63 [0.18 ; 2.25 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Neutropenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.01 [0.00 ; 0.19 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pruritus AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pyrexia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Rash AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
0.95 [0.06 ; 15.23 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Vomiting AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.13 [0.02; 1.09]
0.13 [0.02 ; 1.09 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Weight decreased AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.86 [0.30; 27.64]
2.86 [0.30 ; 27.64 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-31 00:49 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 634,861
